Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 39, Issue 3, 1998, Pages 193-199

  Feinglos, Mark N ^a   Thacker, Connie R ^a   Lobaugh, Bruce ^a   Deatkine, David D ^a   McNeill, Diana B ^a   English, Jennifer S ^a   Bursey, Deborah L ^a  

^a Department of Medicine   (United States)

Author keywords

Insulin; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0031783246     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00003-5     Document Type: Article

References (35)

1. Groop L., Harno K., Nikkila E.A., Pelkonen R., Tolppanen E.M. Transient effect of the combination of insulin and sulfonylurea (glibencalamide) on glycemic control in non-insulin-dependent diabetics poorly controlled with insulin alone. Acta. Med. Scand. 217:1985;33-39.
2. Falko J.M., Osei K. Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation. Am. J. Med. 79(3B):1985;92-101.
3. Allen B.T., Feinglos M.N., Lebovitz H.E. Treatment of poorly regulated non-insulin-dependent diabetes mellitus with combination insulin-sulfonylurea. Arch. Int. Med. 145:1985;1900-1903.
4. Longnecker M.P., Elsenhans V.D., Leiman S.M., Owen O.E., Boden G. Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. Arch. Int. Med. 146:1986;673-676.
5. Gutniak M., Karlander S.G., Efendic S. Glyburide decreases insulin requirement, increases β-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care. 10:1987;545-554.
6. Schade D.S., Mitchell W.J., Greigo G. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind randomized clinical trial. J. Am. Med. Assoc. 257:1987;2441-2445.
7. Lawrence A.M., Abraira C. New modalities in diabetes treatment. Am. J. Med. 85(5A):1988;153-158. (review).
8. Stenman S., Groop P.H., Saloranta C., Totterman K.J., Fyhrqvist F., Groop L. Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycemic agents. Diabetologia. 31:1988;206-213.
9. Riddle M.C., Hart J.S., Bouma D.J., Phillipson B.E., Youkar G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care. 12:1989;623-629.
10. Lewitt M.S., Yu V.K., Rennie G.C. et al. Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care. 12:1989;379-383. (comment).
11. Groop L.C., Widen E., Ekstrand A. et al. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care. 15:1992;831-834.
12. Riddle M., Hart J., Bingham P., Garrison G., McDaniel P. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am. J. Med. Sci. 303:1992;151-156.
13. Mezitis N.H., Heshka S., Saitas V., Bailey T.S., Costa R., Pi-Sunyer F.X. Combination therapy for NIDDM with biosynthetic human insulin and glyburide. Diabetes Care. 15:1992;265-269.
14. Ravnik-Oblak M., Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Res. Clin. Pract. 30:1995;27-35.
15. Chow C., Tsang L.W.W., Sorensen J.P., Cockram C.S. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 18:1995;307-314.
16. Abaira C., Colwell J., Nuttall F. et al. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Diabetes Care. 18:1995;1113-1123.
17. Consensus Statement, The pharmacological treatment of hyperglycemia in NIDDM, Diabetes Care 19 (Suppl. 1) (1996) S54-S61.
18. Stolar M. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism. 2(suppl 1):1988;1-9.
19. Haller H., Drab M., Luft F.C. The role of hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic angiopathy. Clinical Nephrology. 40:1996;246-255.
20. Abaira C., Colwell J., Nuttall F. et al. Cardiovascular events and correlates in the Veterans affairs diabetes feasibility trial. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Arch. Intern. Med. 157:1997;181-188.
21. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann. Intern. Med. 124:1996;104-109.
22. Skyler J.S., Ellis G.J., Skyler D.C. et al. Instructing patients in making alterations in insulin dosage. Diabetes Care. 2:1979;39-45.
23. Klink D.C., Hermanson G.T., Krohn R.I. et al. Determination of glycosylated hemoglobin by affinity chromatography: comparison with colometric and ion exchange methods and effects of common interferences. Clin. Chem. 28:1982;2009-2094.
24. Desbuquois B., Aurbach G.D. Use of polyethylene glycol to separate free and antibody bound peptide hormones in radioimmunoassay. J. Clin. Endocrinol. 33:1971;732-738.
25. Herbert V., Lau K.S., Gottlieb G.W., Blecher S. Coated charcoal immunoassay of insulin. J. Clin. Endocrinol. Metab. 25:1965;1375-1384.
26. Siedel J., Hagele E., Ziegenhorn J., Wahlenfeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin. Chem. 29:1983;1075-1080.
27. McGowan M.W., Artiss J.D., Strandbergh D.R., Zak B. A peroxidase-coupled method for the coloimetric determination of serum triglycerides. Clin. Chem. 29:1983;538.
28. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein in plasma, without use or the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
29. L.D. Fisher, F. van Belle, Biostatistics, John Wiley & Sons, New York, 1993.
30. R.R. Sokal, F.J. Rohlf, Biometry, 2nd edn., W.H. Freeman, San Francisco, 1981.
31. Pugh J.A., Wagner M.L., Sawyer J., Ramirez G., Tuley M., Friedberg S.J. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A meta-analysis. Diabetes Care. 15(8):1992;953-959.
32. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications of IDDM, N. Engl. J. Med. 329 (1993) 683-689.
33. Kaplan N. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Int. Med. 149:1989;1514-1520.
34. Heine R.J. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: part II-'the cons'. Horm. Metab. Res. 28:1996;522-526.
35. Feinglos M.N., Thacker C.H., Lobaugh B., DeAtkine D.D. Jr., McNeill D.B., English J.S. Combination insulin and sulfonylurea therapy in insulin requiring NIDDM. Diabetes. 42(Suppl. 1):1993;55A.